LELAIS GERALD,EPPLE ROBERT,MARSILJE III THOMAS H.,MICHELLYS PIERRE-YVES,MCNEILL MATTHEW H.,LONG YUN,LU WENSHUO,CHEN BEI,BURSULAYA BADRY,JIANG SONGCHUN
申请号：
NZ62766113
公开号：
NZ627661A
申请日:
2013.06.05
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
Disclosed herein are compounds of formula I, where the variables are as defined herein and pharmaceutical compositions thereof, which are useful for modulating EGFR activity. Also disclosed is the use of the compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity. Examples of the compounds of formula I include N-{ 7-chloro-1-[(3R)-1-[4-(pyrrolidin-1-yl)but-2-enoyl]azepan-3-yl]-1H-1,3-benzodiazol-2-yl} -2-methylpyridine-4-carboxamide and (R,E)-N-(7-chloro-1-(1-(4-(pyrrolidin-1-yl)but-2-enoyl)azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide.
